ISRCTN24593488已完成未知
Pomalidomide Specific Targeting in Relapsed and Refractory Myeloma (MUK Seven)
niversity of Leeds (UK)0 个研究点目标入组 250 人开始时间: 2014年3月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current inclusion criteria as of 08/09/2015:
- •1. Diagnosed with symptomatic multiple myeloma and have measurable disease
- •2. Participants must require therapy for relapsed or refractory disease
- •3. Participants must have received = 2 treatment lines of anti-myeloma therapy
- •4. Participants must have received prior treatment with both lenalidomide and proteasome inhibitor, either as single agents or in combination regimens
- •5. All participants must have failed treatment with either lenalidomide or proteasome inhibitor in one of the following three ways:
- •5.1. Documented progressive disease on or within 60 days of completing treatment with lenalidomide and/or proteasome inhibitor
- •5.2. In case of prior response [= partial response (PR)] to lenalidomide or proteasome inhibitor, participants must have relapsed within 6 months after stopping treatment with lenalidomide and/or proteasome inhibitor-containing regimens
- •5.3. Participants who have not had a = minimal response (MR) despite receiving at least 4 cycles of treatment or who have developed intolerance/toxicity after a minimum of two cycles of lenalidomide- and/or proteasome inhibitor-containing regimen
- •6. Participants must have received adequate prior alkylator therapy in one of the following three ways:
- •6.1. As part of a stem cell transplant
- •6.2.A minimum of 4 consecutive cycles of an alkylator based therapy
- •6.3. Progression on treatment with an alkylator; provided that the participant received at least two cycles of an alkylator-containing therapy.
- •7. Life expectancy of at least 3 months
- •8. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
- •9. Required laboratory values: within 14 days of day 1 of treatment
- •9.1. Absolute neutrophil count (ANC) = 1.0 x 109/L (growth factor support is permitted)
- •9.2. Platelet count = 30 x 109/L (platelet transfusion is permitted
- •9.3. Creatinine Clearance > 30 mL/min
- •9.4. Corrected serum calcium =3.5 mmol/L
- •9.5. Haemoglobin = 8 g/dL (blood transfusion support is permitted)
- •9.6. Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) < 3.0 x upper limit of normal (ULN)
- •9.7. Serum total bilirubin < 17µmol/l
- •10. Participants must consent to provide a bone marrow sample
- •11. Able to give informed consent and willing to follow trial protocol
- •12. Aged 18 years or over
- •13. Females of childbearing potential (FCBP) must agree to utilise one reliable form of contraception for 28 days prior to starting trial treatment, during the trial and for 28 days after trial treatment discontinuation and even in case of dose interruption, and must agree to regular pregnancy testing during this timeframe.
- •14. Females must agree to abstain from breastfeeding during trial participation and 28 days after trial drug discontinuation
- •15. Males must agree to use a latex condom during any sexual contact with FCBP during the trial, including during dose interruptions and for 28 days following discontinuation from this trial even if he has undergone a successful vasectomy
- •16. Males must also agree to refrain from donating semen or sperm while on pomalidomide including during any dose interruptions and for 28 days after discontinuation from this trial
- •17. All participants must agree to refrain from donating blood while on trial
- •Previous inclusion criteria:
- •1. Diagnosed with symptomatic multiple myeloma and have measurable disease
- •2. Participants must require therapy for relapsed or refractory disease
- •3. Participants must have received = 2 treatment
排除标准
- •Current exclusion criteria as of 08/09/2015:
- •1. Unable or unwilling to give a bone marrow sample for laboratory analysis.
- •2. Previous therapy with pomalidomide
- •3. Hypersensitivity to thalidomide, lenalidomide, cyclophosphamide or dexamethasone
- •4. Participants with non-secretory multiple myeloma
- •5. Peripheral neuropathy = Grade 3
- •6. Participants who have received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant
- •7. Participants who are planning for a stem cell transplant
- •8. Previous anti-tumour therapies including investigational medicinal products at any dose within 28 days before the start of treatment (or 5 half-lives whichever is longer). Bisphosphonates for bone disease and radiotherapy for palliative intent are permitted
- •9. Chronic use of steroids or any other immunosuppressive therapy
- •10. Participants with any one of the following:
- •10.1. Uncontrolled congestive heart failure
- •10.2. Myocardial infarction within 12 months prior to starting trial treatment
- •10.3. Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris.
- •11. Participants with gastrointestinal disease that may significantly alter absorption of pomalidomide
- •12. Participants unable or unwilling to undergo antithrombotic prophylactic treatment
- •13. Pregnant or breastfeeding females
- •14. Participants known to be seropositive for Human Immunodeficiency Virus (HIV) or active infectious hepatitis A, B or C
- •15. Any conditions including the presence of laboratory abnormalities, which places the participant at unacceptable risk if they were to participate in the trial.
- •16. Participants with a history of other malignancies within 5 years before the date of study entry
- •Previous exclusion criteria:
- •1. Unable or unwilling to give a bone marrow sample for laboratory analysis.
- •2. Previous therapy with pomalidomide
- •3. Hypersensitivity to thalidomide, lenalidomide, or dexamethasone
- •4. Participants with non-secretory multiple myeloma
- •5. Peripheral neuropathy = Grade 3
- •6. Participants who have received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant
- •7. Participants who are planning for a stem cell transplant
- •8. Previous anti-tumour therapies including investigational medicinal products at any dose within 28 days before the start of treatment (or 5 half-lives whichever is longer). Bisphosphonates for bone disease and radiotherapy for palliative intent are permitted
- •9. Chronic use of steroids or any other immunosuppressive therapy
- •10. Participants with any one of the following:
- •10.1. Uncontrolled congestive heart failure
- •10.2. Myocardial infarction within 12 months prior to starting trial treatment
- •10.3. Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris.
- •11. Participants with gastrointestinal disease that may significantly alter absorption of pomalidomide
- •12. Participants unable or unwilling to undergo antithrombotic prophylactic treatment
- •13. Pregnant or breastfeeding females
- •14. Participants known to be seropositive for Human Immunodeficiency Virus (HIV) or active infectious hepatitis A, B or C
- •15. Any conditions including the presence of laboratory abnormalities, which places the participant at unacceptable risk if they were to participate in the trial.
研究者
相似试验
进行中（未招募）
1 期
Pomalidomide Specific Targeting in relapsed and refractory multiple myelomaEUCTR2013-002101-62-GBniversity of Leeds250
终止
1 期
Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom MacroglobulinemiaRecurrent Waldenstrom MacroglobulinemiaRefractory Waldenstrom MacroglobulinemiaNCT01198067M.D. Anderson Cancer Center15
已完成
3 期
Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-DependenceMPN-associated MyelofibrosisPrimary MyelofibrosisNCT01178281Celgene267
进行中（未招募）
1 期
Multi-Center Phase II Study with Pomalidomide in Patients with Myeloproliferative Neoplasms in Fibrotic StageThis is a phase II, multi-center study of pomalidomide in adult patients with Primary myelofibrosis, Secondary myelofibrosis, and unclassifiable Myeloproliferative Neoplasms showing at least grade 1 bone marrow fibrosis and requiring therapy.EUCTR2009-010738-23-DEniversitätsklinikum Ulm95
已完成
2 期
A prospective randomised Phase II study of single agent pomalidomide maintenance versus combination pomalidomide and low dose dexamethasone maintenance following induction with the combination of pomalidomide and low dose dexamethasone in patients with relapsed and refractory myeloma previously treated with lenalidomiderelapsed and refractory multiple myelomaCancer - MyelomaACTRN12612000338864Australasian Leukaemia and Lymphoma Group80